Miranda Jayne Toledano - 29 Dec 2025 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ENTX
Reported as of: 29 Dec 2025
Net transaction value: +$19,912
SEC form: 4
Accepted by SEC: 30 Dec 2025, 06:01:25 UTC
Prior SEC filing: 07 Aug 2025
Next SEC filing: 29 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact

Key filing fact

Miranda Jayne Toledano filed Form 4 for Entera Bio Ltd. (ENTX) on 30 Dec 2025.

Key facts

This page summarizes Miranda Jayne Toledano's Form 4 filing for Entera Bio Ltd. (ENTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Dec 2025, 06:01.

Change

Previous filing in this sequence was filed on 07 Aug 2025.
Current net transaction value: +$19,912.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001686530 Primary reporting owner

Toledano Miranda Jayne

Relationship: Chief Executive Officer, Director
Address: KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM, ISRAEL
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Signature date: 30 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENTX transaction

Ordinary Shares, par value NIS 0.0000769 per share

Purchase

Transaction value: $19,912
Shares: +11,000
Change %: +2.6%
Price: $1.81
Shares after: 426,575
Date: 29 Dec 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.75 to $1.82, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.